GlassScriptPhysician profile
Anne Bowden
NPI 1427485275
$3,658.69
in general payments reported to CMS, 2019-2025
25 companies · $633 in 2025
The $633 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $606 · 2023: $820 · 2024: $1,059 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.19 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $618.59 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $388.93 | 2024-2025 | Korlym |
| Jazz Pharmaceuticals INC. | $362.14 | 2023-2025 | |
| Qol Medical, LLC | $345.17 | 2021-2024 | Sucraid, Sucraid |
| Abbvie INC. | $338.77 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.00 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.42 | 2021-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $176.48 | 2025 | Auvelity |
| Lilly USA, LLC | $123.58 | 2021-2024 | Mounjaro, Reyvow, Emgality |
| Lundbeck LLC | $96.10 | 2022-2024 | Vyepti |
| Harmony Biosciences LLC | $67.28 | 2023 | Wakix |
| Redhill Biopharma INC. | $66.10 | 2021-2022 | |
| Pfizer INC. | $62.83 | 2023-2025 | |
| Novo Nordisk INC | $60.23 | 2021 | |
| Antares Pharma, INC. | $42.28 | 2023 | Xyosted, Nocdurna, Tlando |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $40.34 | 2022 | |
| Amarin Pharma, INC. | $38.04 | 2021 | |
| Acella Pharmaceuticals, LLC | $32.30 | 2024-2025 | NP Thyroid 60 |
| Daiichi Sankyo INC. | $31.60 | 2022 | |
| Genentech USA, INC. | $28.12 | 2023 | Tecentriq |
| Verity Pharmaceuticals INC. | $23.19 | 2025 | Tlando |
| Dexcom, INC. | $22.15 | 2025 | Dexcom G6 Transmitter |
| Arcutis Biotherapeutics, INC. | $20.37 | 2024 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $18.65 | 2022 | |
| Neurelis, INC. | $18.03 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Bowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.